Repositioning: the fast track to new anti-malarial medicines?
暂无分享,去创建一个
Michele Connelly | R Kiplin Guy | Timothy Wells | R. Guy | Pavithra Viswanath | V. Avery | M. Connelly | J. Lotharius | S. Bharath | J. Möhrle | T. Wells | T. Parkinson | Francisco Javier Gamo-Benito | Sandra Duffy | Julie Clark | Iñigo Angulo-Barturen | Vicky M Avery | Julie Lotharius | Iñigo Angulo-Barturen | Balachandra S Bandodkar | Sandra Duffy | Balachandra Bandodkar | Sowmya Bharath | Tanya Parkinson | Julie Clark | Santiago Ferrer-Bazaga | Pavithra Viswanath | Santiago Ferrer-Bazaga | Nikhil Rautela | Jörg J Möhrle | Tanya Parkinson | N. Rautela | Kiplin Guy
[1] J. Adams,et al. Malaria Research and Reference Reagent Resource Center. , 2000, Parasitology today.
[2] V. Avery,et al. Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening , 2012, The American journal of tropical medicine and hygiene.
[3] A. Nzila,et al. A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers , 2011, Malaria Journal.
[4] O. Dar,et al. The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. , 2008, Japanese journal of infectious diseases.
[5] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[6] Cécilie Martin,et al. Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug , 2012, The Journal of infectious diseases.
[7] R. Buxton,et al. New anti-tuberculosis agents amongst known drugs. , 2009, Tuberculosis.
[8] D. Cavalla. APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use , 2009, Nature Reviews Drug Discovery.
[9] A. Cowman,et al. Chemotherapy and drug resistance in malaria. , 1990, International journal for parasitology.
[10] James R. Brown,et al. Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.
[11] J. Bargman,et al. The role of antimalarial agents in the treatment of SLE and lupus nephritis , 2011, Nature Reviews Nephrology.
[12] M. Nystrom. Independent Consultant , 1996 .
[13] P. Roepe,et al. Novel, Rapid, and Inexpensive Cell-Based Quantification of Antimalarial Drug Efficacy , 2004, Antimicrobial Agents and Chemotherapy.
[14] J. McCarthy,et al. Antiretrovirals as antimalarial agents. , 2004, The Journal of infectious diseases.
[15] N. Waters,et al. Targeting protein kinases in the malaria parasite: update of an antimalarial drug target. , 2012, Current topics in medicinal chemistry.
[16] N. White. Artemisinin resistance—the clock is ticking , 2010, The Lancet.
[17] Amanda L. Garner,et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis , 2010, Proceedings of the National Academy of Sciences.
[18] A. Nzila,et al. Methotrexate Is Highly Potent Against Pyrimethamine-Resistant Plasmodium vivax , 2011, The Journal of infectious diseases.
[19] Du Jianwei,et al. Global malaria control and elimination: report of a technical review. , 2010 .
[20] Conor R. Caffrey,et al. Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening , 2009, PLoS neglected tropical diseases.
[21] Stephen T. C. Wong,et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. , 2012, Cancer research.
[22] P. Vachaspati,et al. Fast mouse PK (Fast PK): a rapid screening method to increase pharmacokinetic throughput in pre-clinical drug discovery. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[23] K. Williamson,et al. A High-Throughput Screen Targeting Malaria Transmission Stages Opens New Avenues for Drug Development , 2011, The Journal of infectious diseases.
[24] C. January,et al. Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.
[25] M. Enserink,et al. Did They Really Say ... Eradication? , 2007, Science.
[26] H. Griffin,et al. The European Bioinformatics Institute , 1995 .
[27] M. Wei,et al. Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug , 2011, Journal of biomedicine & biotechnology.
[28] J. McCarthy,et al. The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment , 2012, PloS one.
[29] J. Burrows,et al. The global pipeline of new medicines for the control and elimination of malaria , 2012, Malaria Journal.
[30] M. Enserink,et al. Malaria. Did they really say ... eradication? , 2007, Science.
[31] O. Müller,et al. Haemolysis risk in methylene blue treatment of G6PD‐sufficient and G6PD‐deficient West‐African children with uncomplicated falciparum malaria: a synopsis of four RCTs , 2013, Pharmacoepidemiology and drug safety.
[32] Weltgesundheitsorganisation. World malaria report , 2005 .
[33] F. Cohen,et al. Searching for New Antimalarial Therapeutics amongst Known Drugs , 2006, Chemical biology & drug design.
[34] Francisco-Javier Gamo,et al. Global phenotypic screening for antimalarials. , 2012, Chemistry & biology.
[35] J. Utzinger,et al. Antimalarials in the treatment of schistosomiasis. , 2012, Current pharmaceutical design.
[36] I. Ben-Zvi,et al. Hydroxychloroquine: From Malaria to Autoimmunity , 2011, Clinical Reviews in Allergy & Immunology.
[37] Pawel Dobrzanski,et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. , 2008, Blood.
[38] G. Enders. Mammalian interphase cdks: dispensable master regulators of the cell cycle. , 2012, Genes & cancer.
[39] P. Wilairat,et al. Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening , 2004, Antimicrobial Agents and Chemotherapy.
[40] C. Doerig. Protein kinases as targets for anti-parasitic chemotherapy. , 2004, Biochimica et biophysica acta.
[41] Bruce Russell,et al. Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.
[42] M. Jiménez-Díaz,et al. Quantitative measurement of Plasmodium‐infected erythrocytes in murine models of malaria by flow cytometry using bidimensional assessment of SYTO‐16 fluorescence , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[43] T. Wells,et al. New medicines to improve control and contribute to the eradication of malaria , 2010, Malaria Journal.
[44] O. Müller,et al. Efficacy of methylene blue monotherapy in semi‐immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso , 2010, Tropical medicine & international health : TM & IH.
[45] Anang A. Shelat,et al. Chemical genetics of Plasmodium falciparum , 2010, Nature.
[46] Hoyun Lee,et al. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. , 2009, European journal of pharmacology.
[47] O. Müller,et al. Safety and Efficacy of Methylene Blue Combined with Artesunate or Amodiaquine for Uncomplicated Falciparum Malaria: A Randomized Controlled Trial from Burkina Faso , 2008, PloS one.
[48] L. Shultz,et al. Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.
[49] F. Lang,et al. Effect of cyclosporine on parasitemia and survival of Plasmodium berghei infected mice. , 2008, Biochemical and biophysical research communications.
[50] K. Chibale,et al. Artemisinin derivatives: a patent review (2006 – present) , 2012, Expert opinion on therapeutic patents.
[51] O. Müller,et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine , 2006, Malaria Journal.
[52] D. Zheleva,et al. Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.
[53] Cheng Zhu,et al. Drug repositioning for orphan diseases , 2011, Briefings Bioinform..
[54] P. Rosenthal,et al. A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes , 2008, PloS one.
[55] Yuexin Li,et al. Quinolone-3-Diarylethers: A New Class of Antimalarial Drug , 2013, Science Translational Medicine.
[56] F. Jennings,et al. The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronicT. brucei infections in mice , 2004, Zeitschrift für Parasitenkunde.
[57] David Tweats,et al. Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness , 2010, PLoS neglected tropical diseases.
[58] J. Haynes,et al. Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. , 1983, Experimental parasitology.
[59] A. Nzila,et al. Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species. , 2009, Experimental parasitology.
[60] T. Davis,et al. The metabolism of platelet-activating factor in severe and cerebral malaria. , 1995, The Journal of infection.
[61] Kelly Chibale,et al. Drug repositioning in the treatment of malaria and TB. , 2011, Future medicinal chemistry.
[62] W. Trager,et al. Human malaria parasites in continuous culture. , 1976, Science.
[63] K. El Bissati,et al. Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B , 2007, BMC clinical pharmacology.
[64] J. Haynes,et al. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.
[65] Yongyuth Yuthavong,et al. A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.
[66] A. Nzila,et al. Anticancer agents against malaria: time to revisit? , 2010, Trends in parasitology.
[67] Tao Wu,et al. Road towards new antimalarials - overview of the strategies and their chemical progress. , 2011, Current medicinal chemistry.